Impax Asset Management Group plc Has $10.60 Million Stock Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Impax Asset Management Group plc raised its holdings in SI-BONE, Inc. (NASDAQ:SIBN) by 41.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 758,521 shares of the company’s stock after acquiring an additional 221,604 shares during the quarter. Impax Asset Management Group plc’s holdings in SI-BONE were worth $10,604,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in SI-BONE by 1.8% in the first quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock valued at $40,328,000 after purchasing an additional 43,670 shares during the period. Champlain Investment Partners LLC raised its position in shares of SI-BONE by 104.8% during the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock worth $40,158,000 after acquiring an additional 1,255,610 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of SI-BONE by 22.8% in the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after acquiring an additional 368,637 shares during the period. Paradigm Capital Management Inc. NY boosted its holdings in SI-BONE by 24.7% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock valued at $17,448,000 after acquiring an additional 267,100 shares during the last quarter. Finally, Bellevue Group AG increased its position in SI-BONE by 810.5% during the 1st quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock valued at $18,661,000 after purchasing an additional 1,014,756 shares during the period. Institutional investors own 98.11% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on SIBN. Needham & Company LLC reduced their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Morgan Stanley decreased their price target on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Truist Financial dropped their price objective on SI-BONE from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $22.67.

Insider Buying and Selling at SI-BONE

In related news, insider Anthony J. Recupero sold 2,087 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $14.17, for a total value of $29,572.79. Following the transaction, the insider now directly owns 236,717 shares in the company, valued at $3,354,279.89. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other SI-BONE news, CFO Anshul Maheshwari sold 2,418 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $13.87, for a total transaction of $33,537.66. Following the completion of the sale, the chief financial officer now directly owns 198,762 shares of the company’s stock, valued at approximately $2,756,828.94. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Anthony J. Recupero sold 2,087 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $14.17, for a total value of $29,572.79. Following the completion of the transaction, the insider now owns 236,717 shares in the company, valued at $3,354,279.89. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,676 shares of company stock valued at $344,967. Company insiders own 3.90% of the company’s stock.

SI-BONE Trading Up 6.7 %

SIBN opened at $14.55 on Wednesday. The company has a fifty day moving average price of $14.30 and a two-hundred day moving average price of $14.30. SI-BONE, Inc. has a 1-year low of $11.76 and a 1-year high of $21.70. The company has a market cap of $606.59 million, a P/E ratio of -14.41 and a beta of 1.22. The company has a current ratio of 9.17, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The business had revenue of $39.97 million during the quarter, compared to analyst estimates of $38.95 million. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. During the same period in the previous year, the company posted ($0.30) EPS. Analysts predict that SI-BONE, Inc. will post -0.89 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.